EcoHealth, VinUni and Digital Health Partner to Validate Remedy A.I. in Vietnam

EcoHealth, VinUni and Digital Health Pte Ltd have entered a six-month partnership, running from February to July 2026, to clinically validate Remedy A.I. as a clinical guidance tool for chronic disease management in Vietnam. The project is supported by an Enterprise Singapore grant, reflecting Singapore's wider push to help local companies internationalise and scale healthcare innovation into overseas markets.

The partnership brings together three distinct but complementary organisations. EcoHealth contributes clinical expertise and understanding of care delivery in Vietnam. VinUni provides a research environment for structured validation, academic review and clinical evaluation. Digital Health Pte Ltd contributes Remedy A.I., an applied AI platform designed to support doctors with fast, guideline-aligned chronic disease recommendations.

Why this validation matters

The clinical focus is hyperlipidemia, hypertension and diabetes. These conditions are highly interdependent: blood-pressure targets often change with diabetes or kidney disease, lipid goals depend on cardiovascular-risk stratification, and medication choices must account for renal function, cardiovascular disease, age, adverse effects and local availability.

Remedy A.I.'s value will therefore be tested not as a single-disease chatbot, but as a multi-condition clinical guidance system. The key question is whether the Vietnam modules can reliably reflect Ministry of Health guidance and Vietnam National Heart Association recommendations in real clinical scenarios.

What Remedy A.I. is expected to support

Digital Health describes Remedy A.I. as a localized clinical guidance platform that can generate care plans, apply country-specific guideline logic, support multi-condition planning and provide an evidence trail for recommendations. For clinicians, that evidence trail matters: every recommendation should be traceable to the guideline logic, risk-score inputs and clinical assumptions that produced it.

The aim is not to replace clinicians. Remedy A.I. should function as a clinical guidance layer that helps doctors process complex chronic-disease data more quickly, while leaving clinical judgment, patient discussion, prescribing decisions and final sign-off with the clinician.

Hypertension module

For hypertension, validation will reference Vietnam's Ministry of Health guideline under Decision 3192/QD-BYT, including blood-pressure classification, correct measurement technique, risk-factor assessment and treatment escalation. The module should also reflect the 2022 Vietnamese Society of Hypertension and Vietnam National Heart Association guidance, which defines office hypertension as systolic blood pressure at or above 140 mmHg and/or diastolic blood pressure at or above 90 mmHg, and incorporates home and ambulatory blood-pressure monitoring into diagnosis and management.

Diabetes and prediabetes module

For diabetes, Remedy A.I.'s Vietnam module should align with the Ministry of Health's 2020 type 2 diabetes guideline under Decision 5481/QD-BYT. This includes diagnostic criteria, individualized HbA1c targets, cardiovascular and renal risk assessment, and medication selection based on comorbid atherosclerotic cardiovascular disease, heart failure and chronic kidney disease.

Prediabetes logic should also reference the Ministry of Health's 2020 prediabetes guideline under Decision 3087/QD-BYT, including diagnostic thresholds, risk-factor screening and cardiovascular-risk management.

Hyperlipidemia module

For hyperlipidemia, the Vietnam module should follow Vietnam National Heart Association dyslipidemia recommendations, including cardiovascular-risk estimation, LDL-C target setting, non-HDL-C and ApoB considerations, lifestyle intervention, statin-first therapy, add-on lipid-lowering treatment where targets are not achieved, and special populations such as diabetes, chronic kidney disease, acute coronary syndrome and stroke.

Cardiovascular-risk estimation

Cardiovascular-risk estimation will be a particularly important part of validation. The 2022 VSH/VNHA hypertension update notes that, where Vietnam-specific risk-calculation data are limited, clinicians may use available risk tools such as WHO-ISH Southeast Asia, SCORE2/SCORE2-OP or ASCVD-based approaches depending on the clinical setting. The World Health Organization's updated cardiovascular-risk charts include laboratory and non-laboratory models intended to support risk prediction across global regions, including Southeast Asia.

How the validation should be tested

The validation should test Remedy A.I. against both de-identified clinical cases and structured vignettes. These should include common and edge-case presentations: newly diagnosed hypertension, diabetes with dyslipidemia, statin intolerance, chronic kidney disease, elderly patients with relaxed glycemic targets, high-risk primary prevention, secondary prevention after cardiovascular events, incomplete laboratory data and patients requiring referral.

Key endpoints should include guideline concordance, accuracy of health targets and medication optimization, missing-data handling, and whether every recommendation can be traced back to a guideline source. These endpoints are important because clinical AI should not merely sound plausible; it must show that its recommendations are consistent, auditable and locally appropriate.

Local adoption depends on trust

Safe adoption in Vietnam depends on local guideline alignment, medication availability, referral pathways and clinician trust. A tool that works well in one country cannot simply be copied into another setting without validating the clinical rules, risk thresholds, drug choices and escalation pathways that Vietnamese doctors actually use.

By combining EcoHealth's clinical expertise, VinUni's research environment and Digital Health's applied AI platform, the partnership creates a practical pathway for validating localized clinical intelligence before wider deployment. If successful, the February-July 2026 project will provide evidence that Remedy A.I. can support Vietnamese clinicians in managing hyperlipidemia, hypertension and diabetes with greater consistency, transparency and speed while remaining anchored to Vietnam's own clinical standards.

References

1. Enterprise Singapore: Market Readiness Assistance Grant
2. Enterprise Singapore: Healthcare and Biomedical
3. DigitalHealth.sg: Remedy A.I. | Hyperlocal Clinical Guidance
4. Vietnam Ministry of Health: Decision 3192/QD-BYT hypertension guideline
5. Van Minh H, Van Huy T, Long DPH, Tien HA. Highlights of the 2022 VSH/VNHA hypertension guidelines
6. Vietnam Ministry of Health: Decision 5481/QD-BYT type 2 diabetes guideline
7. Vietnam Ministry of Health: Decision 3087/QD-BYT prediabetes guideline
8. Vietnam National Heart Association
9. Vietnam National Heart Association: 2024 dyslipidemia recommendations summary
10. World Health Organization: WHO updates Cardiovascular Risk Charts